CN109942717A - A kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application - Google Patents
A kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application Download PDFInfo
- Publication number
- CN109942717A CN109942717A CN201910334484.6A CN201910334484A CN109942717A CN 109942717 A CN109942717 A CN 109942717A CN 201910334484 A CN201910334484 A CN 201910334484A CN 109942717 A CN109942717 A CN 109942717A
- Authority
- CN
- China
- Prior art keywords
- ctp
- primer
- fsh
- sequence
- hfsh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 title claims abstract description 34
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims description 14
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 title description 34
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 title description 34
- 229940028334 follicle stimulating hormone Drugs 0.000 title description 34
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 26
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 238000005215 recombination Methods 0.000 claims abstract description 13
- 230000006798 recombination Effects 0.000 claims abstract description 13
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 8
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 claims description 47
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 101150087698 alpha gene Proteins 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 claims description 2
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 208000021267 infertility disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 9
- 108020003175 receptors Proteins 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 230000008521 reorganization Effects 0.000 abstract description 4
- 230000003442 weekly effect Effects 0.000 abstract description 3
- 108010055450 with HCG C-terminal peptide human follicle stimulating hormone Proteins 0.000 abstract description 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 54
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 11
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 11
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 11
- 238000000034 method Methods 0.000 description 6
- 102000002287 alpha Subunit Glycoprotein Hormones Human genes 0.000 description 5
- 108010000732 alpha Subunit Glycoprotein Hormones Proteins 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000002684 recombinant hormone Substances 0.000 description 3
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XELISBQUZZAPQK-CIUDSAMLSA-N Cys-His-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N XELISBQUZZAPQK-CIUDSAMLSA-N 0.000 description 2
- 102000015872 Human beta Subunit Chorionic Gonadotropin Human genes 0.000 description 2
- 108010010590 Human beta Subunit Chorionic Gonadotropin Proteins 0.000 description 2
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 2
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- VIGKUFXFTPWYER-BIIVOSGPSA-N Ala-Cys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N VIGKUFXFTPWYER-BIIVOSGPSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- 108010076441 Ala-His-His Proteins 0.000 description 1
- DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 1
- LXAARTARZJJCMB-CIQUZCHMSA-N Ala-Ile-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LXAARTARZJJCMB-CIQUZCHMSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- DYJJJCHDHLEFDW-FXQIFTODSA-N Ala-Pro-Cys Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N DYJJJCHDHLEFDW-FXQIFTODSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 1
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- XEEIQMGZRFFSRD-XVYDVKMFSA-N Cys-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CS)N XEEIQMGZRFFSRD-XVYDVKMFSA-N 0.000 description 1
- HYKFOHGZGLOCAY-ZLUOBGJFSA-N Cys-Cys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O HYKFOHGZGLOCAY-ZLUOBGJFSA-N 0.000 description 1
- HNNGTYHNYDOSKV-FXQIFTODSA-N Cys-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N HNNGTYHNYDOSKV-FXQIFTODSA-N 0.000 description 1
- ABLQPNMKLMFDQU-BIIVOSGPSA-N Cys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CS)N)C(=O)O ABLQPNMKLMFDQU-BIIVOSGPSA-N 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- NMROINAYXCACKF-WHFBIAKZSA-N Gly-Cys-Cys Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O NMROINAYXCACKF-WHFBIAKZSA-N 0.000 description 1
- IANBSEOVTQNGBZ-BQBZGAKWSA-N Gly-Cys-Met Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O IANBSEOVTQNGBZ-BQBZGAKWSA-N 0.000 description 1
- VNBNZUAPOYGRDB-ZDLURKLDSA-N Gly-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)O VNBNZUAPOYGRDB-ZDLURKLDSA-N 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- QPCVIQJVRGXUSA-LURJTMIESA-N Gly-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QPCVIQJVRGXUSA-LURJTMIESA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- YIFUFYZELCMPJP-YUMQZZPRSA-N Gly-Leu-Cys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O YIFUFYZELCMPJP-YUMQZZPRSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- BIAKMWKJMQLZOJ-ZKWXMUAHSA-N His-Ala-Ala Chemical compound C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O BIAKMWKJMQLZOJ-ZKWXMUAHSA-N 0.000 description 1
- ORZGPQXISSXQGW-IHRRRGAJSA-N His-His-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O ORZGPQXISSXQGW-IHRRRGAJSA-N 0.000 description 1
- BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 1
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 1
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- XDGFFEZAZHRZFR-RHYQMDGZSA-N Met-Leu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDGFFEZAZHRZFR-RHYQMDGZSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WFLWKEUBTSOFMP-FXQIFTODSA-N Pro-Cys-Cys Chemical compound OC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 WFLWKEUBTSOFMP-FXQIFTODSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 1
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- SOACHCFYJMCMHC-BWBBJGPYSA-N Ser-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)O SOACHCFYJMCMHC-BWBBJGPYSA-N 0.000 description 1
- QWMPARMKIDVBLV-VZFHVOOUSA-N Thr-Cys-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O QWMPARMKIDVBLV-VZFHVOOUSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
- VGNLMPBYWWNQFS-ZEILLAHLSA-N Thr-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O VGNLMPBYWWNQFS-ZEILLAHLSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- JVGHIFMSFBZDHH-WPRPVWTQSA-N Val-Met-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N JVGHIFMSFBZDHH-WPRPVWTQSA-N 0.000 description 1
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention proposes a kind of recombination hFSH-Fc fusion protein, the fusion protein is dimeric fusion protein, and one of single amino acid sequence is followed successively by hFSH β subunit, CTP, CTP and hFSH α subunit from N-terminal to C-terminal；Another single amino acid sequence is followed successively by CTP, hFSH α subunit, hFSH β subunit and CTP from N-terminal to C-terminal.Two CTP are connected on the coded sequence of FSH by the present invention, are avoided the region combined to receptor or bioactivity is important, are not influenced receptor binding affinity, are not had immunogenicity, can significantly be extended volume lifetime.Meanwhile the half-life period of FSH-CTP in vivo is longer, end-stage half-life period is 2-3 times of reorganization FSH-WT, and can be weekly to inject instead of injecting 7 times a day, and bioactivity is higher.
Description
Technical field
The present invention relates to biomedicine technical fields, and in particular to a kind of long-acting recombinant human follicle-stimulating hormone (FSH).
Background technique
Currently, infertility rate is up to 15% in world wide, becomes except cancer and cardiovascular and cerebrovascular disease, seriously affect
The third-largest disease of human health.China's infertility number accounts for 10% or more reproduction number of women, and its disease incidence is on obvious
The trend of liter.Human follicle-stimulating element (Human follicle-stimulating hormone, abbreviation hFSH) is that existing market is common
For treating the main ingredient of male and female infertility drug.
Human follicle-stimulating element (Human Follicle-stimulating hormone, abbreviation hFSH) is one kind by pituitary
The promoting sexual gland hormone of anterior secrets is necessary to male and female normal reproductive function.Follicular stimulating hormone and luteotropin
(LH), human chorionic gonadotropin (hCG), thyroid-stimulating hormone (TSH) collectively constitute glycoprotein hormones family.These hormones
To be formed by two subunits, α and β, α subunit be it is universal, β subunit is specific.Follicle-stimulating hormone (FSH) is used clinically for stimulating
Folliculus ovarii development progress is in vitro fertilization, to obtain more egg mother cells.In male, FSH is found to adjusting and maintains
Spermiogenesis tail process is most important.After using FSH, rear sperm ultrastrueture and locomitivity are obviously improved.Follicle-stimulating hormone it
Purifying is for clinic in the preceding urine from elderly woman.However identification FSH β and α gene enables DNA technique dynamic in lactation
Reorganization FSH is generated in object cell and is mankind's use.
Since the half-life period of FSH is relatively short, it is injected daily in the past.Therefore, it is necessary to develop long-acting heavy
Group FSH (rhFSH), to reduce administration number of times.In order to overcome this problem, other researchers describe a kind of increase rhFSH
The method of half-life period introduces the chain glycosylation site of new n- by site directed mutation.The result shows that the addition chain carbon of n-
Hydrate chain has no effect on the folding of hormone or the binding affinity with receptor, meanwhile, increase the half-life period of animal model
And in vivo bioactivity.But this strategy may change the structure of FSH, and triggering immune response in vivo.These are similar
Object is not detected in clinical studies, and immunogenicity spectrum is unclear.
Summary of the invention
In order to solve the above technical problems, the present invention provides a kind of long-acting recombinant human follicle-stimulating hormone (FSH) and preparation method thereof
And application, it is intended that a kind of long-acting recombinant human follicle-stimulating hormone (FSH) is provided, by that will include 4 O-linked oligosaccharides sites
CTP peptide be connected to the coded sequence of FSH subunit, this structure and alpha subunit co-transfection are arrived with mammalian expression vector
In Chinese hamster ovary cell (CHO), generate dimer recombinant hormone, this combine the folding to the assembling of subunit, protein, by
Body binding affinity and Bioactivity are without influence.
The present invention provides a kind of recombination hFSH-Fc fusion protein, and the fusion protein is dimeric fusion protein, wherein one
A single amino acid sequence is followed successively by hFSH β subunit, CTP, CTP and hFSH α subunit from N-terminal to C-terminal；Another single amino acid
Sequence is followed successively by CTP, hFSH α subunit, hFSH β subunit and CTP from N-terminal to C-terminal；
The amino acid sequence of the hFSH β subunit is as shown in SEQ ID NO:1；The amino acid sequence of the CTP such as SEQ
Shown in ID NO:2；The amino acid sequence of the hFSH α subunit is as shown in SEQ ID NO:3.
The present invention further protects a kind of preparation method of above-mentioned recombination hFSH-Fc fusion protein, comprising: poly- using overlapping
The mosaic gene of synthase chain reaction building CTP sequence and FSH β subunit；Mosaic gene is cloned into containing LTR/CMV promoter
In carrier for expression of eukaryon；The carrier in combination of the subunit of α containing FSH of building and FSH β subunit is transfected into Chinese hamster ovary cell
In, filter out the cell strain for stablizing expression；The FSH variant in the culture medium for carrying out the cell strain of self-stabilization expression is collected, and pure
Change obtains recombination hFSH fusion protein
As further improvement of the invention, the building of the mosaic gene includes the following steps: that S1. constructs FSH β-
CTP；S2. FSH β (CTP) 2 is constructed；The building of S3.CTP- α mosaic gene.
As further improvement of the invention, step S1's includes the following steps:
(1) using FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH β of a restriction site
5 ' terminal sequences, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 is held comprising FSH β sequence 3 '
Rear 4 base codes and CTP sequence first four base code, primer 4 include CTP sequence 3 ' hold 4 base codes and a restriction site.
(3) for reacting the DNA profiling of No. 1 and No. 2, it is used as the template of primer 1 and 4, to amplify FSH β-CTP.
As further improvement of the invention, specific step is as follows by step S2:
(1) use FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH of a restriction site
5 ' terminal sequence of β, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β CTP sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 contains FSH β-CTP sequence
Rear 4 base codes at 3 ' ends and preceding 4 base codes of CTP sequence, primer 4 contain the 4 base codes and an agretope that CTP sequence 3 ' is held
Point；
(3) it is used in the DNA profiling of reaction No. 1 and No. 2, as the template of primer 1 and 4, to amplify FSH β-(CTP) 2.
As further improvement of the invention, specific step is as follows by step S3:
(1) use hCG β gene as the template of primer hCG β 1 and 2, wherein primer 1 includes the CTP of a restriction site
5 ' terminal sequences, primer 2 include alpha subunit preceding 4 base codes and CTP sequence 3 ' hold rear 4 base codes；
(2) use α gene as the template of primer 3 and primer 4, wherein rear 43 ' end groups of the primer 3 containing CTP sequence
Preceding 4 base codes of code and α sequence, primer 4 contain the 4 base codes and a restriction site that α sequence 3 ' is held；
(3) it is used in the DNA profiling of reaction No. 1 and No. 2, as the template of primer 1 and 4, is fitted into base to amplify CTP- α
Cause.
The present invention further protects a kind of pharmaceutical composition, includes pharmaceutically acceptable carrier or excipient or dilution
Agent and a effective amount of above-mentioned recombination hFSH-Fc fusion protein.
The present invention further protects above-mentioned recombination hFSH-Fc fusion protein to treat answering in infertile disease drug in preparation
With.
The present invention further protects above-mentioned recombination hFSH-Fc fusion protein preparing answering in animal reproduction field of medicament
With.
The invention has the following beneficial effects: the present invention to be connected to the CTP peptide comprising 4 O-linked oligosaccharides sites
The coded sequence of FSH subunit is thin to Chinese hamster ovary with alpha subunit co-transfection by this structure with mammalian expression vector
In born of the same parents (CHO), dimer recombinant hormone is generated.The result shows that this is combined to the assembling of subunit, the folding of protein, receptor knot
Affinity and Bioactivity are closed without influence.Two CTP are connected on the coded sequence of FSH, avoid to receptor combine or
The important region of bioactivity, does not influence receptor binding affinity, does not have immunogenicity, can significantly extend volume lifetime.Together
When, the half-life period of FSH-CTP in vivo is longer, and end-stage half-life period is 2-3 times of reorganization FSH-WT, and can be weekly to infuse
It penetrates instead of injecting 7 times a day, bioactivity is higher.
Detailed description of the invention
Fig. 1 is the schematic diagram of FSH variant (A) of the embodiment of the present invention 1 comprising HCG β carboxy terminal peptide (CTP) sequence；
Fig. 2 is the schematic diagram of FSH variant (A) of the embodiment of the present invention 2 comprising HCG β carboxy terminal peptide (CTP) sequence.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, the embodiment described is the embodiment of part of representative of the invention, rather than whole embodiments, this field are general
Other all embodiments obtained belong to protection of the invention to logical technical staff without making creative work
Range.
A kind of recombination hFSH-Fc fusion protein, the fusion protein are dimeric fusion protein, one of monomer amino
Acid sequence is followed successively by hFSH β subunit, CTP, CTP and hFSH α subunit from N-terminal to C-terminal, such as attached drawing 1；Another single amino acid sequence
Column are followed successively by CTP, hFSH α subunit, hFSH β subunit and CTP from N-terminal to C-terminal, such as attached drawing 2.
The amino acid sequence of the hFSH β subunit is as shown in SEQ ID NO:1；The amino acid sequence of the CTP such as SEQ
Shown in ID NO:2；The amino acid sequence of the hFSH α subunit is as shown in SEQ ID NO:3
Embodiment 1
Referring to attached drawing 1, two CTP sequences are connected to the carboxyl terminal of FSH β subunit with overlapping PCR method.In LTR/
Under the action of CMV promoter, mosaic gene is sequenced, is cloned into carrier for expression of eukaryon.Describe the sequence of amino acid containing CTP
The amino acid sequence (B) of the FSH α and FSH β subunit of the modification of column.By the clone containing FSH α and the FSH β subunit of modification
Carrier in combination is transfected into CHO, the production for recombinant protein.
The preparation method is as follows:
S1. FSH β-CTP is constructed；
(1) using FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH β of a restriction site
5 ' terminal sequences, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 is held comprising FSH β sequence 3 '
Rear 4 base codes and CTP sequence first four base code, primer 4 include CTP sequence 3 ' hold 4 base codes and a restriction site.
(3) for reacting the DNA profiling of No. 1 and No. 2, it is used as the template of primer 1 and 4, to amplify FSH β-CTP.
S2. FSH β (CTP) 2 is constructed；
(1) using FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH β of a restriction site
5 ' terminal sequences, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 is held comprising FSH β sequence 3 '
Rear 4 base codes and CTP sequence first four base code, primer 4 include CTP sequence 3 ' hold 4 base codes and a restriction site.
(3) for reacting the DNA profiling of No. 1 and No. 2, it is used as the template of primer 1 and 4, to amplify FSH β-CTP.
The building of S3.CTP- α mosaic gene；
(1) using FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH β of a restriction site
5 ' terminal sequences, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 is held comprising FSH β sequence 3 '
Rear 4 base codes and CTP sequence first four base code, primer 4 include CTP sequence 3 ' hold 4 base codes and a restriction site.
(3) for reacting the DNA profiling of No. 1 and No. 2, it is used as the template of primer 1 and 4, to amplify FSH β-CTP.
Embodiment 2
Referring to attached drawing 2, CTP sequence is connected to the N-terminal of FSH α and the c-terminus of FSH β subunit with overlapping PCR method.
Under the action of LTR/CMV promoter, mosaic gene is sequenced, is cloned into carrier for expression of eukaryon.Describe ammonia containing CTP
The amino acid sequence (B) of the FSH α and FSH β subunit of base acid sequence.By the clone of the FSH α and FSH β subunit containing modification
Carrier in combination is transfected into CHO, carries out recombinant protein production.
The preparation method is as follows:
S1. FSH β-CTP is constructed；
(1) using FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH β of a restriction site
5 ' terminal sequences, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 is held comprising FSH β sequence 3 '
Rear 4 base codes and CTP sequence first four base code, primer 4 include CTP sequence 3 ' hold 4 base codes and a restriction site.
The building of S2.CTP- α mosaic gene；
(1) using FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH β of a restriction site
5 ' terminal sequences, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 is held comprising FSH β sequence 3 '
Rear 4 base codes and CTP sequence first four base code, primer 4 include CTP sequence 3 ' hold 4 base codes and a restriction site.
Compared with prior art, the CTP peptide comprising 4 O-linked oligosaccharides sites is connected to FSH subunit by the present invention
Coded sequence, with mammalian expression vector by this structure and alpha subunit co-transfection to Chinese hamster ovary cell (CHO)
In, generate dimer recombinant hormone.The result shows that this is combined to the assembling of subunit, the folding of protein, receptor binding affinity
With Bioactivity without influence.Two CTP are connected on the coded sequence of FSH, are avoided to receptor combination or bioactivity
Important region does not influence receptor binding affinity, does not have immunogenicity, can significantly extend volume lifetime.Meanwhile FSH-
The half-life period of CTP in vivo is longer, and end-stage half-life period is 2-3 times of reorganization FSH-WT, and can be weekly to inject replacement
It injects 7 times a day, bioactivity is higher.
Those skilled in the art is not under conditions of departing from the spirit and scope of the present invention that claims determine, also
Various modifications can be carried out to the above content.Therefore the scope of the present invention is not limited in above explanation, but by
The range of claims determines.
Sequence table
<110>Shanghai Yan founds pharmaceutcal corporation, Ltd
<120>a kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 157
<212> PRT
<213>artificial sequence (artificial sequence)
<400> 1
Met Leu Thr Leu Gly Pro Pro Pro Leu Pro Cys Cys Thr Leu Ala Ile
1 5 10 15
Cys Cys Ala Ser Cys Gly Leu Thr Ala Ile Thr Ile Ala Ile Gly Leu
20 25 30
Gly Gly Cys Ala Pro Cys Ile Ser Ile Ala Thr Thr Thr Cys Ala Gly
35 40 45
Thr Cys Thr Thr Ala Ala Leu Val Thr Leu Ala Pro Ala Ala Pro Leu
50 55 60
Ile Gly Leu Thr Cys Thr Pro Leu Gly Leu Val Thr Gly Thr Val Ala
65 70 75 80
Val Pro Gly Cys Ala His His Ala Ala Ser Leu Thr Thr Thr Pro Val
85 90 95
Ala Thr Gly Cys His Cys Gly Leu Cys Ala Ser Ala Ser Thr Ala Cys
100 105 110
Thr Val Ala Gly Leu Gly Pro Ser Thr Cys Ser Pro Gly Gly Met Leu
115 120 125
Gly Ser Ser Ser Ser Leu Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser
130 135 140
Ala Leu Pro Gly Pro Ser Ala Thr Pro Ile Leu Pro Gly
145 150 155
<210> 2
<211> 29
<212> PRT
<213>artificial sequence (artificial sequence)
<400> 2
Ser Ser Ser Ser Leu Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Ala
1 5 10 15
Leu Pro Gly Pro Ser Ala Thr Pro Ile Leu Pro Gly Met
20 25
<210> 3
<211> 123
<212> PRT
<213>artificial sequence (artificial sequence)
<400> 3
Ala Pro Ala Val Gly Gly Thr Gly Pro His His Val Ala Gly Ala Ala
1 5 10 15
Leu Leu Leu Leu Ser Ser Ser Ala Pro Pro Thr Leu Ala Ser Gly Ser
20 25 30
Ala Ala Ile Thr Ala Cys Pro Gly Cys Thr Leu Gly Gly Ala Pro Pro
35 40 45
Pro Ser Gly Pro Gly Ala Pro Ile Leu Gly Cys Met Gly Cys Cys Pro
50 55 60
Ser Ala Ala Thr Pro Thr Pro Leu Ala Ser Leu Leu Thr Met Leu Val
65 70 75 80
Gly Leu Ala Val Thr Ser Gly Ser Thr Cys Cys Val Ala Leu Ser Thr
85 90 95
Ala Ala Val Thr Val Met Gly Gly Pro Leu Val Gly Ala His Thr Ala
100 105 110
Cys His Cys Ser Thr Cys Thr Thr His Leu Ser
115 120
Claims (9)
1. a kind of recombination hFSH-Fc fusion protein, which is characterized in that the fusion protein is dimeric fusion protein, wherein one
A single amino acid sequence is followed successively by hFSH β subunit, CTP, CTP and hFSH α subunit from N-terminal to C-terminal；Another single amino acid
Sequence is followed successively by CTP, hFSH α subunit, hFSH β subunit and CTP from N-terminal to C-terminal；
The amino acid sequence of the hFSH β subunit is as shown in SEQ ID NO:1；The amino acid sequence of the CTP such as SEQ ID
Shown in NO:2；The amino acid sequence of the hFSH α subunit is as shown in SEQ ID NO:3.
2. recombinating the preparation method of hFSH-Fc fusion protein described in a kind of claim 1 characterized by comprising utilize overlapping
The mosaic gene of polymerase chain reaction building CTP sequence and FSH β subunit；Mosaic gene is cloned into containing LTR/CMV promoter
Carrier for expression of eukaryon in；The carrier in combination of the subunit of α containing FSH of building and FSH β subunit is transfected into Chinese hamster ovary cell
In, filter out the cell strain for stablizing expression；The FSH variant in the culture medium for carrying out the cell strain of self-stabilization expression is collected, and pure
Change obtains recombination hFSH fusion protein.
3. a kind of preparation method for recombinating hFSH-Fc fusion protein according to claim 2, which is characterized in that described chimeric
The building of gene includes the following steps: that S1. constructs FSH β-CTP；S2. FSH β (CTP) 2 is constructed；The structure of S3.CTP- α mosaic gene
It builds.
4. a kind of preparation method for recombinating hFSH-Fc fusion protein according to claim 3, which is characterized in that step S1's
Include the following steps:
(1) using FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes that the FSH β 5 ' an of restriction site is held
Sequence, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 includes rear 4 that FSH β sequence 3 ' is held
The first four base code of a base code and CTP sequence, primer 4 include the 4 base codes and a restriction site that CTP sequence 3 ' is held.
(3) for reacting the DNA profiling of No. 1 and No. 2, it is used as the template of primer 1 and 4, to amplify FSH β-CTP.
5. a kind of preparation method for recombinating hFSH-Fc fusion protein according to claim 3, which is characterized in that step
Specific step is as follows by S2:
(1) use FSH β gene as the template of primer 1 and primer 2, wherein primer 1 includes the FSH β 5 ' of a restriction site
Terminal sequence, primer 2 include rear 4 base codes of preceding 4 base codes of CTP and 3 ' ends of FSH β CTP sequence；
(2) template of the hCG β-CTP gene as primer 3 and primer 4 is used, wherein primer 3 is held containing FSH β-CTP sequence 3 '
Rear 4 base codes and CTP sequence preceding 4 base codes, primer 4 contain CTP sequence 3 ' hold 4 base codes and a restriction site；
(3) it is used in the DNA profiling of reaction No. 1 and No. 2, as the template of primer 1 and 4, to amplify FSH β-(CTP) 2.
6. a kind of preparation method for recombinating hFSH-Fc fusion protein according to claim 3, which is characterized in that step
Specific step is as follows by S3:
(1) use hCG β gene as the template of primer hCG β 1 and 2, wherein primer 1 includes the 5 ' of the CTP of a restriction site
Terminal sequence, primer 2 include preceding 4 base codes of alpha subunit and rear 4 base codes that CTP sequence 3 ' is held；
(2) use α gene as the template of primer 3 and primer 4, wherein rear 43 ' end group codes of the primer 3 containing CTP sequence and
Preceding 4 base codes of α sequence, primer 4 contain the 4 base codes and a restriction site that α sequence 3 ' is held；
(3) it is used in the DNA profiling of reaction No. 1 and No. 2, as the template of primer 1 and 4, to amplify CTP- α mosaic gene.
7. a kind of pharmaceutical composition, which is characterized in that include pharmaceutically acceptable carrier or excipient or diluent, Yi Jiyou
The recombination hFSH-Fc fusion protein described in claim 1 of effect amount.
8. recombination hFSH-Fc fusion protein described in claim 1 treats the application in infertile disease drug in preparation.
9. the recombination hFSH-Fc fusion protein of claim 1 is preparing the application in animal reproduction field of medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910334484.6A CN109942717A (en) | 2019-04-24 | 2019-04-24 | A kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910334484.6A CN109942717A (en) | 2019-04-24 | 2019-04-24 | A kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109942717A true CN109942717A (en) | 2019-06-28 |
Family
ID=67016100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910334484.6A Pending CN109942717A (en) | 2019-04-24 | 2019-04-24 | A kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109942717A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111704676A (en) * | 2020-07-17 | 2020-09-25 | 上海延立药业有限公司 | Long-acting recombinant erythropoietin and preparation method and application thereof |
| CN112195194A (en) * | 2020-10-30 | 2021-01-08 | 北京双鹭生物技术有限公司 | Recombinant human follicle stimulating hormone and preparation method thereof |
| CN113717291A (en) * | 2021-09-17 | 2021-11-30 | 南通大学 | Ultra-long-acting stable FSH, expression recombination method thereof and assisted reproduction technology |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5759818A (en) * | 1991-10-04 | 1998-06-02 | Washington University | N-terminal CTP extended pharmaceutical peptides and proteins |
| CN103554268A (en) * | 2013-11-01 | 2014-02-05 | 广州诺新生物技术有限公司 | Long-acting recombinant follicle-stimulating hormone and application thereof |
| CN106163543A (en) * | 2013-10-21 | 2016-11-23 | 奥普科生物制品有限公司 | Long-acting polypeptides and generation and the method casting it |
| CN107286248A (en) * | 2016-08-19 | 2017-10-24 | 安源医药科技（上海）有限公司 | High-glycosylation human growth hormone (HGH) fusion protein and preparation method thereof and purposes |
| CN107540748A (en) * | 2017-09-15 | 2018-01-05 | 北京伟杰信生物科技有限公司 | Long-acting Recombinant Swine FSH fusion proteins and preparation method and application |
| CN108676096A (en) * | 2018-05-22 | 2018-10-19 | 北京伟杰信生物科技有限公司 | Recombinant Swine FSH-CTP fusion proteins and the preparation method and application thereof |
-
2019
- 2019-04-24 CN CN201910334484.6A patent/CN109942717A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5759818A (en) * | 1991-10-04 | 1998-06-02 | Washington University | N-terminal CTP extended pharmaceutical peptides and proteins |
| CN106163543A (en) * | 2013-10-21 | 2016-11-23 | 奥普科生物制品有限公司 | Long-acting polypeptides and generation and the method casting it |
| CN103554268A (en) * | 2013-11-01 | 2014-02-05 | 广州诺新生物技术有限公司 | Long-acting recombinant follicle-stimulating hormone and application thereof |
| CN107286248A (en) * | 2016-08-19 | 2017-10-24 | 安源医药科技（上海）有限公司 | High-glycosylation human growth hormone (HGH) fusion protein and preparation method thereof and purposes |
| CN107540748A (en) * | 2017-09-15 | 2018-01-05 | 北京伟杰信生物科技有限公司 | Long-acting Recombinant Swine FSH fusion proteins and preparation method and application |
| CN108676096A (en) * | 2018-05-22 | 2018-10-19 | 北京伟杰信生物科技有限公司 | Recombinant Swine FSH-CTP fusion proteins and the preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| RHONDA K TROUSDALE等: "Single-chain bifunctional vascular endothelial growth factor (VEGF)-follicle-stimulating hormone (FSH)-C-terminal peptide (CTP) is superior to the combination therapy of recombinant VEGF plus FSH-CTP in stimulating angiogenesis during ovarian folliculogene", 《ENDOCRINOLOGY》 * |
| 刁勇等: "长效卵泡刺激素的分子设计与新药开发", 《药学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111704676A (en) * | 2020-07-17 | 2020-09-25 | 上海延立药业有限公司 | Long-acting recombinant erythropoietin and preparation method and application thereof |
| CN112195194A (en) * | 2020-10-30 | 2021-01-08 | 北京双鹭生物技术有限公司 | Recombinant human follicle stimulating hormone and preparation method thereof |
| CN113717291A (en) * | 2021-09-17 | 2021-11-30 | 南通大学 | Ultra-long-acting stable FSH, expression recombination method thereof and assisted reproduction technology |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7081446B2 (en) | Long-acting follicle stimulating hormone analogues and uses thereof | |
| RU2537268C2 (en) | Recombinant follicle-stimulating hormone (fsh) containing alpha-2, 3- and alpha-2, 6-syalilation | |
| JP6580104B2 (en) | Pharmaceutical formulation | |
| KR102014469B1 (en) | Composition for controlled ovarian stimulation | |
| WO2003094858A2 (en) | Ctp-extended erythropoietin | |
| WO2015062350A1 (en) | Long-acting recombinant follicle-stimulating hormone and use thereof | |
| CN109942717A (en) | A kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application | |
| CN102260343A (en) | Application of recombinant human G-CSF dimer for treating nerve damage disease | |
| WO2015062349A1 (en) | Long-acting recombinant human follicle-stimulating hormone-fc fusion protein | |
| CN103554269B (en) | Recombinant porcine follicle-stimulating hormone-Fc fusion protein (pFSH-Fc) | |
| JP6336557B2 (en) | Pharmaceutical formulation | |
| CN118562018B (en) | Recombinant follicle-stimulating hormone fusion protein | |
| WO1998021238A1 (en) | Recombinant single-stranded equine chorionic gonadotropin | |
| JP2000509603A (en) | Glycoprotein hormone super agonist | |
| JP7681684B2 (en) | Growth hormone fusion proteins and methods for their preparation and use | |
| CN111704676A (en) | Long-acting recombinant erythropoietin and preparation method and application thereof | |
| Fima et al. | Enhancing the Potency and Longevity of Highly Valuable Peptides Using Gene Fusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190628 |